Cytoreductive Gastrectomy After Systemic Therapy Versus Systemic Therapy Alone For Limited Metastasis Gastric Cancer

This trial is comparing two treatment strategies for gastric (stomach) cancer that has spread to a limited number of other areas: surgery to remove the primary stomach tumor after initial systemic therapy, versus continuing systemic therapy alone without surgery. It aims to determine if removing the primary tumor in addition to chemotherapy leads to better outcomes. **You may be eligible if...** - You have stomach cancer with limited spread (called limited metastatic disease, including peritoneal, liver, or lymph node involvement meeting specific criteria) - You are between 18 and 75 years old with good performance status (ECOG below 1) - Your cancer has been confirmed by tissue biopsy or cytology - You are fit for potential surgery following initial systemic treatment **You may NOT be eligible if...** - Your cancer has spread extensively beyond the defined limited metastatic criteria - Your general health is too poor to handle surgery - You have more than two separate organ sites of metastasis - You do not meet the laboratory or organ function requirements Talk to your doctor to see if this trial is right for you.